TY  - BOOK
AU  - Ihemelandu, Chukwuemeka
AU  - Sugarbaker, Paul H
TI  - Management for Peritoneal Metastasis of Colonic Origin: Role of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy: A Single Institution's Experience During Two Decades
SN  - 1068-9265
PY  - 2017///
KW  - *Antineoplastic Combined Chemotherapy Protocols/ad [Administration & Dosage]
KW  - *Colonic Neoplasms/pa [Pathology]
KW  - *Cytoreduction Surgical Procedures
KW  - *Peritoneal Neoplasms/sc [Secondary]
KW  - *Peritoneal Neoplasms/th [Therapy]
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Biomarkers, Tumor/bl [Blood]
KW  - CA-125 Antigen/bl [Blood]
KW  - Capecitabine/ad [Administration & Dosage]
KW  - Chemotherapy, Adjuvant
KW  - Female
KW  - Fluorouracil/ad [Administration & Dosage]
KW  - Follow-Up Studies
KW  - Humans
KW  - Infusions, Parenteral
KW  - Male
KW  - Middle Aged
KW  - Mitomycin/ad [Administration & Dosage]
KW  - Mucin-1/bl [Blood]
KW  - Neoadjuvant Therapy
KW  - Neoplasm, Residual
KW  - Organoplatinum Compounds/ad [Administration & Dosage]
KW  - Retrospective Studies
KW  - Survival Rate
KW  - Young Adult
KW  - MedStar Washington Hospital Center
KW  - Washington Cancer Institute
KW  - Surgery/General Surgery
KW  - Journal Article
N1  - Available online from MWHC library: 1994 - present
N2  - BACKGROUND: Peritoneal metastasis of colonic origin is associated with a poor prognosis. This study aimed to analyze the clinicopathologic characteristics and prognostic predictors of survival in a cohort of patients treated with cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy (POIC) during two decades; CONCLUSION: For patients with a limited extent of peritoneal metastases, CC is the most important prognostic variable for improved survival of colon cancer patients with peritoneal metastases; METHODS: A retrospective study analyzed a prospectively maintained database for all patients treated for peritoneal metastasis of a colonic origin (PCC) from January 1990 to April 2015; RESULTS: The 318 patients in our study comprised 171 men (53.8%) and 147 women (46.2%). The mean age of the patients at presentation was 50.6 years, (range 18-86 years). Overall survival was 42.5%, median survival and follow-up time was 21.5 and 15.0 months respectively. The 3 and 5 years survival rates were respectively 35 and 25%. The median survival time was 20.6 months for the men and 23.1 months for the women (p = 0.14). The mean intraoperative peritoneal carcinomatosis index (PCI) was 15.2. The patients who had a completeness of cytoreduction (CC) score of 0 or 1 (no residual disease <0.25 mm) had a median survival time of 36.6 months compared with 18.3 months for the patients with a CC-2 score and 7.6 months for the patients with a CC-3 score (p < 0.000). The significant independent predictors of survival in the multivariate analysis were the CC score and elevated tumor makers CA153 and CA125
UR  - https://dx.doi.org/10.1245/s10434-016-5698-x
ER  -